TABLE 1.

Patient demographic, clinical, and recording characteristics

Subject	Age, years	Sex	Implant location	Seizure types	Antiepileptic drugs	Recording duration, days	Recording adherence, %	Number of EEG seizures	Number of lead seizures (training/testing)a
E02	33	F	LT	FIAS, FBTCS	LMT, CLBb BRVc LEVb PRPb,c	89	70	24	15 (3/10)
E04	38	F	LT	Uncertain	LCM, ESL	69	90	12	12 (3/6)
E06	75	F	LT	FIAS, FBTCS	LCM, LMT	76	62	17	15 (8/4)
E09	27	F	LT	FAS	None	84	80	25	25 (8/11)
S01	36	F	LT	FAS, FIAS	CBZ, LEV	230	84	30	18 (4/11)
S02	57	M	RT	FAS, FIAS	CBZ, BRV, CLBd	46	73	35	18 (9/5)

Abbreviations: BRV, brivaracetam; CBZ, carbamazepine; CLB, clobazam; EEG, electroencephalographic; ESL, eslicarbazepine; F, female; FAS, focal aware seizures; FBTCS, focal to bilateral tonic–clonic seizures; FIAS, focal impaired awareness seizures; LCM, lacosamide; LEV, levetiracetam; LMT, lamotrigine; LT, left temporal; M, male; PRP, perampanel; RT, right temporal.

^aSeizures separated from preceding seizures by at least 4 h. Note that a proportion of seizures from each patient were not available for training or testing, due to insufficient or no preictal recording.

^bStopped during monitoring.

^cStarted during monitoring.

^dRescue antiseizure medication.